{"id":8665,"date":"2023-01-27T08:35:05","date_gmt":"2023-01-27T14:35:05","guid":{"rendered":"https:\/\/ibio.org\/?p=8665"},"modified":"2023-01-27T08:35:49","modified_gmt":"2023-01-27T14:35:49","slug":"clostrabio-announces-breakthrough-publication-describing-targeted-delivery-of-metabolite-to-gastrointestinal-tract-via-oral-nanoparticles-appoints-ce","status":"publish","type":"post","link":"https:\/\/ibio.org\/clostrabio-announces-breakthrough-publication-describing-targeted-delivery-of-metabolite-to-gastrointestinal-tract-via-oral-nanoparticles-appoints-ce\/","title":{"rendered":"ClostraBio Announces Breakthrough Publication Describing Targeted Delivery of Metabolite to Gastrointestinal Tract via Oral Nanoparticles; Appoints CE"},"content":{"rendered":"

CHICAGO–(BUSINESS WIRE<\/a><\/span>)–ClostraBio, a biotech company focused on developing novel therapeutic solutions for diseases of the gut, is excited to announce a major breakthrough in targeted metabolite delivery to transform intestinal health. This first-in-class, oral, targeted metabolite delivery platform enables butyrate to achieve its maximum therapeutic potential with an initial focus on helping patients who struggle with gastrointestinal issues like mild to moderate ulcerative colitis and food allergies.<\/p>\n

Business Wire Link: https:\/\/www.businesswire.com\/news\/home\/20230124005835\/en\/ClostraBio-Announces-Breakthrough-Publication-Describing-Targeted-Delivery-of-Metabolite-to-Gastrointestinal-Tract-via-Oral-Nanoparticles-Appoints-CEO<\/a><\/p>\n

\n

\u201cWe have created an innovative way to use polymeric nanoparticles to address delivery of butyrate to the lower gut to help patients with mild to moderate ulcerative colitis and food allergy\u201d<\/p>\n

Tweet this<\/span><\/p><\/blockquote>\n

This groundbreaking development of an oral nanoparticle platform has the potential to revolutionize the treatment of gut-related diseases and marks a significant step forward in the field of gastrointestinal health (source: University of Chicago release<\/a>). Until now, oral delivery of sodium butyrate had been a challenge due to not only its foul odor and taste, but because it metabolized too rapidly to maintain a pharmacologic effect in the small intestine and colon, the areas of the gut where it has a therapeutic effect.<\/p>\n

\u201cWe have created an innovative way to use polymeric nanoparticles to address delivery of butyrate to the lower gut to help patients with mild to moderate ulcerative colitis and food allergy,\u201d said ClostraBio founder, Dr. Cathryn Nagler. \u201cThis new therapeutic has the potential to help patients by restoring normal barrier protective function over time.\u201d<\/p>\n

In a recent study published in the journal Nature Biomedical Engineering<\/a><\/i>, ClostraBio\u2019s founders, Dr. Cathryn Nagler, Dr. Jeffrey Hubbell, and co-authors demonstrated that the use of polymeric nanoscale micelles can effectively restore intestinal homeostasis in mouse models of colitis and peanut allergy. Butyrate was selected for its ability to alleviate inflammatory diseases of the gut through multiple mechanisms. ClostraBio co-founder, Dr. Jeffrey Hubbell said, \u201cIn today\u2019s options for gastrointestinal issues, targeted drug delivery has become key in pharmaceutical product development. Innovative, sustained-release technologies allow for increased performance of new and existing compounds.\u201d<\/p>\n

In addition to this exciting news, ClostraBio is pleased to announce a key addition to its management team with the appointment of CEO, Ritu Shah, Managing Director at Portal Innovations and taking on leadership roles at Portal\u2019s portfolio companies.<\/p>\n

\u201cI\u2019m honored to serve as the CEO at ClostraBio. The science and technology behind their metabolite delivery platform, along with Dr. Nagler and Dr. Hubbell\u2019s long-term vision is what attracted me to the company,\u201d said Shah. \u201cAfter the successful delivery of the drug in mice as featured in Nature Biomedical Engineering,<\/i> I\u2019m excited to execute a go-to-market plan to help bring visibility of ClostraBio to the marketplace where more than 33 million Americans suffer from inflammatory bowel disease (IBD) and food allergies.\u201d<\/p>\n

Shah joins ClostraBio with over two decades of experience in multiple leadership roles in drug development for pharma and biotech. She was recently Chief Operating Officer at Pyxis Oncology. To date, Shah helped take Pyxis public, while also completing mergers and acquisitions with four biotech and pharmaceutical companies.<\/p>\n

\u201cAt ClostraBio, our novel delivery platform is designed to transform the treatment of lower gut disease \u2014starting with ulcerative colitis,\u201d finished Shah.<\/p>\n

About ClostraBio<\/p>\n

ClostraBio is a late-preclinical stage biopharma company focused on targeted metabolite delivery to transform intestinal health in patients with inflammatory bowel disease (IBD) and food allergy. Founded on seminal science originating from Dr. Cathryn Nagler\u2019s and Dr. Jeffrey Hubbell\u2019s labs at the University of Chicago, the company is developing a novel nanoparticle platform that enables oral delivery of short-chain fatty acids (SCFAs) to targeted locations in the gastrointestinal tract. For more information about the company, please visit: http:\/\/clostrabio.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

CHICAGO–(BUSINESS WIRE)–ClostraBio, a biotech company focused on developing novel therapeutic solutions for diseases of the gut, is excited to announce a major breakthrough in targeted metabolite delivery to transform intestinal health. This first-in-class, oral, targeted metabolite delivery platform enables butyrate to achieve its maximum therapeutic potential with an initial focus on helping patients who struggle […]<\/p>\n","protected":false},"author":12,"featured_media":8668,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[145],"tags":[396,262,202,121],"class_list":["post-8665","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-community-news","tag-biotech","tag-chicago","tag-clostrabio","tag-illinois"],"_links":{"self":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/8665","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/comments?post=8665"}],"version-history":[{"count":1,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/8665\/revisions"}],"predecessor-version":[{"id":8667,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/posts\/8665\/revisions\/8667"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/media\/8668"}],"wp:attachment":[{"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/media?parent=8665"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/categories?post=8665"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibio.org\/wp-json\/wp\/v2\/tags?post=8665"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}